But recurrent tumors are more likely to be invasive, lowering overall survival rate
Monday, May 2, 2011 (Last Updated: 05/03/2011)
MONDAY, May 2 (HealthDay News) -- Patients with ductal carcinoma in situ (DCIS) who undergo radiation therapy in addition to excision have a longer time to recurrence, but recurrent tumors are more likely to be invasive, according to a study presented at the annual meeting of the American Society of Breast Surgeons, held from April 27 to May 1 in Washington, D.C.
Janie Weng Grumley, M.D., from the University of Southern California in Los Angeles, and colleagues evaluated whether radiation therapy affected the pattern of local recurrence and breast cancer-specific survival. Patients with pure DCIS who underwent excision alone (651 patients), and 363 patients who underwent excision plus radiation therapy were analyzed for the type of local recurrence (invasive versus DCIS), average time to recurrence, quadrant of recurrence (same or different), and breast cancer-specific survival.
The investigators found that, compared to patients who were not irradiated, those who underwent irradiation had a significantly lower 10-year probability of recurrence, longer time to diagnosis of recurrence, and a slightly but significantly lower 10-year breast cancer-specific survival. Significantly more patients who were irradiated had recurrence in different quadrants (28 versus 10 percent), and recurrent tumors were more likely to be invasive compared to those who underwent excision alone (57 versus 37 percent).
"Irradiated patients who recurred took longer to recur. This was true for both invasive and DCIS recurrences. When irradiated patients recurred, they had a higher percentage of invasive recurrences. This resulted in a statistically significant lower 10-year breast cancer-specific survival," the authors write.
Hematology & Oncology
Copyright © 2011 HealthDay. All rights reserved.